← INTERSTELLAR BLENDS
GOAL · THE PATHWAYS BEHIND IT

Cholesterol & Triglycerides

8 biological pathways sit behind this goal. Each is named, defined in plain English, and carries the strength of the published human evidence for it.

The pathways

What is behind Cholesterol & Triglycerides

1Triglycerides — The Circulating Fat

Circulating fat in transit. More responsive to carbohydrate load and alcohol than to dietary fat — a counterintuitive fact that makes this a sharper dietary readout than cholesterol. Evidence A — Human trial evidence.

2Lipid Metabolism — How Fats Are Handled

The transport and handling of fats, not simply their level. Particle number, size and oxidation state carry more predictive weight than total cholesterol — a distinction the mainstream number obscures. Evidence A — Human trial evidence.

3Fatty-Acid Synthesis — The Fat Factory

Fatty-acid synthesis — the de-novo line that converts surplus carbohydrate into stored fat and liver triglyceride. Evidence A — Human trial evidence.

4Weight & Body Fat — Body Weight

How much body fat you carry, shown by body weight, BMI and waist size. Higher means more fat. Where fat sits matters too: fat around the belly and organs (visceral fat) carries more health risk than fat under the skin, and muscle is tracked separately. Evidence A — Human trial evidence.

5Hepatic Steatosis — The Fat in the Liver

Hepatic steatosis — the accumulation of fat in the liver, the first step of metabolic liver disease. Evidence A — Human trial evidence.

6Nitric oxide/eNOS

Nitric-oxide blood-vessel relaxation and flow. Evidence A — Human trial evidence.

7NF-κB — The Immune Alarm

The master inflammatory switch — indispensable to defend against threat, corrosive when it never stands down. Evidence B — Preclinical.

8Adiponectin — The Metabolic Ally

An adipose-derived hormone that sharpens insulin sensitivity and steers fat toward burning rather than storage. Evidence A — Human trial evidence.

Evidence on these pathways

NF-κB → CD38 NADase. “Regulation of CD38 expression in HASM cells involves the transcription factor NF-κB, and glucocorticoids inhibit this expression through NF-κB-dependent and -independent mechanisms.” — Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-α and dexamethasone. Respiratory Research, 2008, vol 9, 26. doi:10.1186/1465-9921-9-26

NF-κB → COX-2 Induction. “Moreover, the nuclear factor kappa B (NF-κB) inhibitor BAY11‐7085 or the TLR4 neutralizing antibody markedly blocked PM2.5-induced IL-6 and COX-2 expression.” — PM2.5 exposure upregulates pro-inflammatory protein expression in human microglial cells via oxidant stress and TLR4/NF-κB pathway. Ecotoxicology and Environmental Safety, 2024, vol 277, article 116386. doi:10.1016/j.ecoenv.2024.116386

NF-κB → Kynurenine Pathway. “Treatment of vaccinated DCs with pharmacological NF-κB inhibitors ACHP or DHMEQ significantly inhibited IDO1 biosynthesis, suggesting a role for NF-κB signaling in vaccine up-regulation of dendritic cell IDO1.” — Induction of Indoleamine 2, 3-Dioxygenase in Human Dendritic Cells by a Cholera Toxin B Subunit—Proinsulin Vaccine. PLoS ONE, 2015, volume 10, e0118562. doi:10.1371/journal.pone.0118562

NF-κB → Muscle Recovery. “Activation of NF-κB in skeletal muscle leads to degradation of specific muscle proteins, induces inflammation and fibrosis, and blocks the regeneration of myofibers after injury/atrophy.” — Nuclear factor-kappa B signaling in skeletal muscle atrophy. Journal of Molecular Medicine, 2008, volume 86, issue 10, pages 1113-1126. doi:10.1007/s00109-008-0373-8

Formulas that act on these pathways

1Ceramide Blocker

Acts on 6 of these pathways: Lipid Metabolism, Fatty-Acid Synthesis, Weight & Body Fat, Hepatic Steatosis, NF-κB, Adiponectin.

2Galectin Inhibitor

Acts on 5 of these pathways: Lipid Metabolism, Fatty-Acid Synthesis, Weight & Body Fat, Hepatic Steatosis, NF-κB.

3NRF2 Activator

Acts on 4 of these pathways: Lipid Metabolism, Weight & Body Fat, Hepatic Steatosis, NF-κB.

4Hormesis

Acts on 4 of these pathways: Lipid Metabolism, Weight & Body Fat, NF-κB, Adiponectin.

5Holy Grail

Acts on 4 of these pathways: Lipid Metabolism, Fatty-Acid Synthesis, Weight & Body Fat, Hepatic Steatosis.

6Helico

Acts on 4 of these pathways: Lipid Metabolism, Weight & Body Fat, NF-κB, Adiponectin.

What this page does not claim

This page names the pathways involved and the published evidence on each. It does not claim that any formula treats, cures or prevents Cholesterol & Triglycerides. A pathway opens here only on graded, published evidence, under a standard fixed before the evidence was gathered, and every figure above carries its grade.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Every pathway named, with the published study behind it.  ·  interstellarblends.com ·  Sign in